What is generalized myasthenia gravis?
Generalized myasthenia gravis, or gMG, is an autoimmune condition that affects how nerves and muscles communicate.1 This page offers a plain-language overview for people who want to understand the condition better as they consider the UPSTREAM MG clinical study.
How gMG happens, in plain language.
In generalized myasthenia gravis, the body's immune system makes antibodies that can interfere with the signals nerves send to muscles. When those signals are disrupted, muscles may not respond as they should, leading to weakness.2,3
Symptoms can vary and may change over time.
gMG symptoms can vary from person to person and may change over time, even from day to day. People with gMG may experience muscle weakness that affects different parts of the body.2
Eye muscles
Drooping eyelids or double vision.2
Face and throat
Difficulty speaking, swallowing, or changes in facial expression.2
Neck and limbs
Weakness in arms, legs, or holding up the head.2
Breathing muscles
In some people, weakness of the muscles used for breathing.2
Overactive bladder
An increased risk of urinary incontinence and urgency.4
Everyday impacts look different for every person.
Muscle weakness and fatigue can affect daily activities—from climbing stairs to holding a conversation. Many people describe symptoms that improve with rest.5 How gMG shows up is different for everyone, and care is individualized.
Clinical studies are how new approaches get tested.
Researchers are working to better understand gMG and study new approaches that may help people living with the condition. Clinical studies are part of how researchers learn whether investigational medicines may be safe and effective.6
The UPSTREAM MG study is one such research effort, evaluating an investigational medicine called telitacicept in adults with gMG.
References
Medically reviewed · May 2026
- A study of telitacicept for the treatment of generalized myasthenia gravis (UPSTREAM MG). ClinicalTrials.gov identifier: NCT06456580. Updated May 7, 2026. Accessed May 14, 2026. https://clinicaltrials.gov/study/NCT06456580
- National Institute of Neurological Disorders and Stroke. Myasthenia gravis. National Institutes of Health. Accessed April 22, 2026. https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
- Hoffman M. Insights into the current and future treatment of myasthenia gravis. NeurologyLive. January 18, 2023. Accessed April 29, 2026. https://www.neurologylive.com/view/insights-into-the-current-and-future-treatment-of-myasthenia-gravis
- Shihada K, Gorenshtein A, Wolfe GI, Shelly S. Urinary dysfunction in myasthenia gravis: a cross-sectional case-control study. Neurol Sci. 2026;47(91):1-11.
- Myasthenia Gravis Foundation of America. What is myasthenia gravis (MG)? Accessed April 22, 2026. https://myasthenia.org/understanding-mg/what-is-myasthenia-gravis
- US Food and Drug Administration. The drug development process—step 3: clinical research. Updated January 4, 2018. Accessed April 22, 2026. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
Ready to take the next step?
Registering takes about a minute and is not a commitment to join the study.